-
Tytuł:
-
Prognostic value of a 15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy.
-
Autorzy:
-
Deschuymer S; Department of Radiation Oncology, University Hospitals Leuven, KU Leuven - University of Leuven, Herestraat 49, 3000, Leuven, Belgium.
Sørensen BS; Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Dok R; Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven - University of Leuven, Leuven, Belgium.
Laenen A; Leuven Biostatistics and Statistical Bioinformatics Center, University Hospitals Leuven, KU Leuven - University of Leuven, Leuven, Belgium.
Hauben E; Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven - University of Leuven, Leuven, Belgium.
Overgaard J; Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Nuyts S; Department of Radiation Oncology, University Hospitals Leuven, KU Leuven - University of Leuven, Herestraat 49, 3000, Leuven, Belgium. .; Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven - University of Leuven, Leuven, Belgium. .
-
Źródło:
-
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2020 Jun; Vol. 196 (6), pp. 552-560. Date of Electronic Publication: 2020 Feb 20.
-
Typ publikacji:
-
Comparative Study; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [München] : Urban & Vogel, [c1986-
-
MeSH Terms:
-
Chemoradiotherapy*/methods
Diffusion Magnetic Resonance Imaging*
Genes, p16*
Carcinoma, Squamous Cell/*therapy
Cell Hypoxia/*genetics
Oropharyngeal Neoplasms/*therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Alkylating/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Carcinoma, Squamous Cell/chemistry ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/mortality ; Cetuximab/therapeutic use ; Cisplatin/therapeutic use ; Female ; Follow-Up Studies ; Gene Expression Profiling ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Oropharyngeal Neoplasms/chemistry ; Oropharyngeal Neoplasms/genetics ; Oropharyngeal Neoplasms/mortality ; Oxygen/analysis ; Prognosis ; Treatment Outcome
-
Contributed Indexing:
-
Keywords: Accelerated radiotherapy; Biomarker; Chemoradiotherapy; Hypoxia gene classifier; Oropharyngeal cancer
-
Substance Nomenclature:
-
0 (Antineoplastic Agents, Alkylating)
0 (Antineoplastic Agents, Immunological)
PQX0D8J21J (Cetuximab)
Q20Q21Q62J (Cisplatin)
S88TT14065 (Oxygen)
-
Entry Date(s):
-
Date Created: 20200222 Date Completed: 20201211 Latest Revision: 20201214
-
Update Code:
-
20240105
-
DOI:
-
10.1007/s00066-020-01595-y
-
PMID:
-
32080773
-
Purpose: A 15-gene hypoxia classifier has been developed and validated as a predictive factor for patients with head and neck squamous cell carcinoma treated with radiotherapy and nimorazole. This paper aimed to investigate the role of this hypoxia classifier as a prognostic factor for patients with oropharyngeal cancer (OPC) treated with accelerated chemoradiotherapy.
Methods: P16 and 15-gene hypoxia classifier status, categorising tumours as more or less hypoxic, were determined for 136 OPC patients. Locoregional recurrence rate (LRR) and overall survival (OS) were estimated with cumulative incidence function and Kaplan-Meier method, respectively, stratified according to p16 and hypoxia status.
Results: P16-positive patients (34.6%) had significantly better LRR and OS than p16-negative patients. The 5‑year LRR of patients with more hypoxic OPC was similar to those with less hypoxic OPC in the overall patient population (27.3% versus 25.1%; p = 0.98; HR = 1.01 [CI95% 0.47;2.17]) and in the p16-negative OPC (36.4% versus 30.1%; p = 0.70; HR = 1.17 [CI95% 0.53;2.56]). No significant OS differences could be observed in neither p16-negative nor p16-positive subgroup with a 5-year OS for p16-negative more hypoxic OPC of 44.2% versus 49.0% in the less hypoxic OPC (p = 0.92; HR 0.97 [CI95% 0.51;1.84]).
Conclusion: No significant outcome differences were observed between more or less hypoxic tumours, as determined by the 15-gene hypoxia classifier. These results suggest that the 15-gene hypoxia classifier may not have prognostic value in an OPC patient cohort treated with accelerated chemoradiotherapy.
